Indexed with PubMed and Science Citation Index (E) 
Users online: 1514 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
    Next article
    Previous article
    Table of Contents

    Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded98    
    Comments [Add]    

Recommend this journal


Year : 2017  |  Volume : 83  |  Issue : 4  |  Page : 432--435

Expression of the receptor for advanced glycation end products in acquired reactive perforating collagenosis

1 Department of Dermatovenereology, Ataturk Training and Research Hospital, Ankara, Turkey
2 Department of Pathology, Ataturk Training and Research Hospital, Ankara, Turkey
3 Department of Biostatistics, School of Medicine, Kastamonu University, Kastamonu, Turkey

Correspondence Address:
Gulsen Akoglu
Department of Dermatovenereology, Ankara Ataturk Training and Research Hospital, Bilkent, Ankara
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijdvl.IJDVL_113_16

Rights and Permissions

Background: Acquired reactive perforating collagenosis (ARPC) is a rare skin disorder characterized by transepidermal elimination of dermal collagen. There is little data regarding the pathogenesis of ARPC. The receptor for advanced glycation end products (RAGE) is a multiligand transmembrane receptor that plays an important role in inflammatory responses and may be involved in the pathogenesis of ARPC. Aim: To explore the expression of RAGE in ARPC. Methods: Paraffin-embedded punch biopsy specimens of 41 patients with ARPC and of 11 healthy controls with normal skin were obtained from the Department Of Pathology. Clinical data of all patients were reviewed from the medical files. All specimens were stained immunohistochemically with antibody to RAGE (Anti-RAGE). The intensity of RAGE expression was assessed semi-quantitatively on epidermal cells, microvascular endothelium, dermal fibroblasts and inflammatory cells and graded as 0 (no staining), 1 (weak), 2 (moderate) and 3 (strong). The patients were divided into diabetic and nondiabetic groups for analysis. Results: RAGE expression in microvascular endothelium, inflammatory cells and fibroblasts of patients with ARPC was more intense than normal tissues of healthy participants (P values are 0.005, 0.017 and <0.001, respectively). The grade of RAGE expression was comparable in diabetic and nondiabetic patients (all P > 0.05). Limitations: Our method of assessment of RAGE expression was semi-quantitative. Conclusion: We observed an overexpression of RAGE in lesional samples of patients with ARPC which was independent of the presence of diabetes.


Print this article     Email this article

Online since 15th March '04
Published by Wolters Kluwer - Medknow